Skip to main content
    D

    DNA X, Inc. (SONM)

    Official site

    FINANCIAL SERVICES • COMMUNICATION EQUIPMENT • NASDAQ

    $2.12
    -0.05 (-2.30%)

    Market Cap: $3.23M

    Last updated: Nov 17, 2026 at 11:02 AM ET

    DNA X, Inc. (SONM) Financials: Revenue, Profit and Cash Flow

    Updated Aug 19, 2026. Financial statements from company filings, amounts in US dollars.

    DNA X reported revenue of $0 for the fiscal year ended Dec 31, 2025. That year, net income was -$20.66M, operating cash flow was -$23.53M and free cash flow was -$23.53M. The quarter ended Jun 30, 2026 had revenue of -$11.00K and net income of -$1.25M.

    Revenue and Margins

    The company reported no revenue in the fiscal year ended Dec 2025, with an operating loss of $5.41M.

    Fiscal yearRevenueGrowthGross marginOperating marginNet margin
    Dec 2025$0N/AN/AN/AN/A
    Dec 2024$0-100.0%N/AN/AN/A
    Dec 2023$93.63M+34.1%20.6%0.5%-0.1%
    Dec 2022$69.83M+28.0%16.6%-20.5%-20.2%
    Dec 2021$54.57M-14.7%11.8%-69.6%-70.8%
    Dec 2020$63.99M-45.0%23.8%-45.7%-46.8%
    Dec 2019$116.25M-14.3%29.7%-19.3%-22.2%
    Dec 2018$135.66M+129.8%35.4%4.0%0.9%
    Dec 2017$59.03MN/A34.4%-11.5%-14.4%
    Dec 2000$2.85MN/A39.6%N/AN/A
    Annual, fiscal years ended Dec 2000 to Dec 2025

    Income Statement

    In the fiscal year ended Dec 2025, the net loss narrowed from the year before. In the quarter ended Jun 2026, the net loss narrowed from the same quarter a year earlier.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2000
    Revenue$0$0$93.63M$69.83M$54.57M$63.99M$116.25M$135.66M$59.03M$2.85M
    Cost of revenue$0$0$74.31M$58.20M$48.16M$48.78M$81.74M$87.58M$38.72M$1.72M
    Gross profit$0$0$19.32M$11.62M$6.41M$15.21M$34.51M$48.09M$20.31M$1.13M
    Research and development$0$0$1.77M$7.97M$17.70M$16.22M$26.06M$23.25M$13.01M$0
    Operating income-$5.41M-$3.10M$513.00K-$14.29M-$38.00M-$29.26M-$22.38M$5.39M-$6.77MN/A
    Net income-$20.66M-$33.65M-$90.00K-$14.09M-$38.63M-$29.93M-$25.83M$1.28M-$8.52MN/A
    EBITDA-$2.01M$703.00K$2.50M-$11.43M-$36.33M-$26.64M-$19.31M$5.71M-$6.25MN/A
    Fiscal years ended Dec 2000 to Dec 2025

    Quarterly

    Line itemJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Revenue-$11.00K$0-$44.13M$16.21M$0$0-$43.31M$15.02M$11.52M$16.78M$13.43M$27.57M
    Gross profit-$11.00K$0-$11.02M$1.82M$0$0-$10.10M$4.23M$2.97M$2.90M$5.12M$5.60M
    Operating income-$1.28M-$3.62M$4.66M-$3.98M-$1.47M-$870.00K$8.44M-$2.38M-$6.47M-$2.69M-$1.25M$688.00K
    Net income-$1.25M$6.34M-$8.89M-$4.75M-$7.47M$458.00K-$21.61M-$2.51M-$6.62M-$2.91M-$1.35M$527.00K
    Last 12 quarters

    Balance Sheet

    As of Dec 2025, short-term debt of $5.07M exceeded cash and equivalents by $3.76M. Shareholder equity was negative, at -$7.96M, as total liabilities of $50.63M exceeded total assets of $43.90M.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2000
    Total assets$43.90M$39.74M$56.04M$53.69M$41.09M$50.31M$55.46M$67.34M$30.25M$1.05M
    Current assets$28.91M$32.16M$43.79M$43.63M$35.69M$45.57M$47.34M$63.87M$27.37MN/A
    Cash and equivalents$1.30M$5.34M$9.40M$13.21M$11.23M$22.14M$11.30M$13.05M$1.58M$103.00K
    Total liabilities$50.63M$45.44M$33.67M$33.64M$22.46M$21.90M$29.93M$62.22M$39.76M$4.05M
    Short-term debt$5.07M$0$55.00K$147.00K$148.00K$177.00K$9.82M$301.00K$3.13MN/A
    Long-term debtN/AN/AN/AN/A$66.00K$185.00K$362.00K$13.21M$7.55M$351.00K
    Shareholder equity-$7.96M-$5.70M$22.37M$20.05M$18.63M$28.41M$25.52M$5.13M-$9.51M-$2.99M
    Fiscal years ended Dec 2000 to Dec 2025

    Quarterly

    Line itemJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Total assets$4.52M$4.84M$43.90M$40.22M$36.08M$35.96M$39.74M$49.15M$45.87M$42.38M$56.04M$58.61M
    Total liabilities$5.75M$4.92M$50.63M$40.92M$37.41M$37.04M$45.44M$33.80M$28.40M$22.55M$33.67M$35.50M
    Cash and equivalents$900.00K$1.20M$1.30M$2.14M$2.01M$2.12M$5.34M$9.06M$9.60M$9.25M$9.40M$9.80M
    Shareholder equity-$1.23M-$983.00K-$6.73M-$701.00K-$1.33M-$1.08M-$5.70M$15.35M$17.47M$19.84M$22.37M$23.11M
    Last 12 quarters

    Cash Flow

    Operating cash flow was negative in the fiscal year ended Dec 2025.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017
    Operating cash flow-$23.53M-$8.49M-$4.05M-$12.36M-$38.48M-$10.56M-$33.52M$3.86M-$8.91M
    Capital expenditures$0$214.00K$36.00K$8.00K$46.00K$11.00K$1.36M$2.54M$1.17M
    Free cash flow-$23.53M-$8.70M-$4.09M-$12.37M-$38.52M-$10.57M-$34.88M$1.32M-$10.08M
    Dividends paidN/AN/AN/AN/AN/A$6.00K$1.90MN/AN/A
    Investing cash flow$0-$214.00K-$36.00K-$8.00K-$46.00K-$11.00K-$1.36M-$2.54M-$999.00K
    Financing cash flow$19.49M$4.65M$272.00K$14.35M$27.61M$21.41M$33.13M$10.15M$4.42M
    Fiscal years ended Dec 2017 to Dec 2025

    Quarterly

    Line itemJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Operating cash flow-$2.00M-$3.47M-$2.00M-$7.03M-$4.88M-$9.61M-$4.51M-$417.00K-$3.39M-$168.00K-$351.00K-$304.00K
    Capital expendituresN/A$0$0$0$0$8.00K$8.00K$137.00K$39.00K$30.00K$12.00K$1.00K
    Free cash flowN/A-$3.47M-$2.00M-$7.03M-$4.88M-$9.61M-$4.52M-$554.00K-$3.43M-$198.00K-$363.00K-$305.00K
    Last 12 quarters

    Frequently Asked Questions About SONM

    What is DNA X's annual revenue?

    DNA X reported revenue of $0 for the fiscal year ended Dec 31, 2025.

    Is DNA X profitable?

    No. DNA X reported net income of -$20.66M for the fiscal year ended Dec 31, 2025.

    How much free cash flow does SONM generate?

    For the fiscal year ended Dec 31, 2025, operating cash flow of -$23.53M minus capital expenditures of $0 produced free cash flow of -$23.53M.

    How much debt does DNA X have?

    The balance sheet dated Dec 31, 2025 reported short-term debt of $5.07M and cash and equivalents of $1.30M.